Correction: Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide

June 24, 2026BJC ReportsOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

To investigate how molecular subtypes of glioblastoma influence the tumor's response to temozolomide in vitro.
Analysis of various glioblastoma molecular subtypes.
In vitro experiments to evaluate response to temozolomide.
Identification of relevant non-coding RNAs involved in the response.
Certain molecular subtypes exhibit a significantly higher response to temozolomide than others.
Specific non-coding RNAs correlate with the sensitivity to temozolomide treatment.
Findings suggest that molecular profiling could aid in personalizing glioblastoma therapies.

Answers are grounded in this paper and cite their sources.

Correction reports on how different glioblastoma molecular subtypes respond to temozolomide in vitro, suggesting tailored treatment strategies.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Rancati et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share